Clinical update: intravenous iron for anaemia

Lancet

Volumn 369, Issue 9572, 2007, Pages 1502-1504

  Auerbach, Michael ^a   Ballard, Harold ^b   Glaspy, John ^c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; COSMOFER; DEXTRAN; DIPHENHYDRAMINE; FERRIC GLUCONATE; FERRITIN; HEMOSIDERIN; HEPCIDIN; HYPERTENSIVE FACTOR; IRON; IRON DEXTRAN; IRON SACCHARATE; IRON SALT; METHYLPREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG COST; DRUG DOSE REGIMEN; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INJECTION SITE REACTION; IRON DEFICIENCY ANEMIA; LABORATORY TEST; MONOTHERAPY; MYALGIA; PERIORBITAL EDEMA; PRIORITY JOURNAL; REPEATED DRUG DOSE; SARCOMA; SINGLE DRUG DOSE; SKIN DISCOLORATION; STRIDOR; TACHYCARDIA; THORAX PAIN; UNSPECIFIED SIDE EFFECT; WHEEZING;

EID: 34247615981     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60689-8     Document Type: Note

References (20)

1. Kanakaraddi V., Hoskatti C., Nadig V., Patil C., and Maiya M. Comparative therapeutic study of TDI and IM injections of iron dextran complex in anaemia. J Assoc Physicians India 21 (1973) 849-853
2. Hamstra R., Block M., and Schocket A. Intravenous iron dextran in clinical medicine. JAMA 243 (1980) 1726-1731
3. Auerbach M., Witt D., Toler W., Fierstein M., Lerner R., and Ballard H. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 111 (1988) 566-570
4. Auerbach M., Winchester J., Wahab A., et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 31 (1998) 81-86
5. Fishbane S., Ungureanu V., Maesaka J., Kaupke C., Lim V., and Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28 (1996) 529-534
6. Fishbane S., Mittal S., and Maesaka J. Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int 55 (1999) S67-S70
7. Adamson J., and Eschbach J. Erythropoietin for end-stage renal disease. N Engl J Med 339 (1998) 625-627
8. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 (2003) 783-788
9. Andrews N. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 113 (2004) 1251-1253
10. Auerbach M., Ballard H., Trout J., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22 (2004) 1301-1307
11. Henry D., Dahl N., Auerbach M., Tchekmedyian S., and Laufman L. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12 (2007) 231-242
12. Hedenus M., Birgegård G., Näsman P., et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia (2007). published online Jan 25. DOI:10.1038/sj.leu.2404562
13. Macdougall I., Cavill I., Hulme B., et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 304 (1992) 225-226
14. Tessitore N., Solero G., Lippi G., et al. The role of iron status markers in predicting response to intravenous iron in hemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16 (2001) 1416-1423
15. Chertow G., Mason P., Vaage-Nilsen O., and Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 19 (2004) 1571-1575
16. Chertow G., Mason P., Vaage-Nilsen O., and Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21 (2006) 378-382
17. Auerbach M., Chaudhry M., Goldman H., and Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med 131 (1998) 257-260
18. Chandler G., Harchowal J., and Macdougall I. Intravenous iron sucrose: Establishing a safe dose. Am J Kid Dis 38 (2001) 988-991
19. MacDougall I., and Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2297 injections. Am J Kidney Dis 46 (2005) 283-289
20. Fishbane S., Frei G., and Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26 (1995) 41-46